Jianting Sheng,Ju Young Ahn,Li Yang et al.
Jianting Sheng et al.
Large language models (LLMs) have demonstrated impressive capabilities in summarization, reasoning, and content generation, yet their inability to directly interpret large-scale omics data has limited their utility in data-driven hypothesis...
Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial [0.03%]
Yu-Ping Zhou,Lu-Hong Qiu,Wei Ma et al.
Yu-Ping Zhou et al.
Pulmonary arterial hypertension (PAH) has a poor prognosis despite available treatments. TPN171H, structurally modified from traditional Chinese medicine (Epimedium), was reported to have a high affinity for phosphodiesterase type 5 and exh...
ADAMTS4 elicits myeloid-derived immune cell recruitment and liver fibrogenesis in metabolic dysfunction-associated steatotic liver disease [0.03%]
ADAMTS4通过募集髓系衍生的免疫细胞诱导代谢功能异常相关肝脂肪变性疾病的肝纤维化
Jeongwoo Park,Taeeung Kim,Wan Seob Shim et al.
Jeongwoo Park et al.
A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) has been implicated in arthritis and lung fibroblast activation; however, its role in liver homeostasis and fibrogenesis remains largely unexplored. Here, we investi...
Antagonistic pleiotropy in disease tolerance: Foxo1-Trim63 axis as double-edged sword in age-dependent sepsis [0.03%]
Foxo1-Trim63轴在年龄依赖性脓毒症中作为疾病耐受性的双重刃剑作用
Unbin Chae,Jin-Man Kim,Young-Ho Park
Unbin Chae
Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial [0.03%]
特瑞普利单抗(O药)联合乐伐替尼不可切除肝癌新适应症II期临床试验（SISENSE研究）
Shichun Lu,Wenwen Zhang,Junfeng Li et al.
Shichun Lu et al.
Our previous findings demonstrated the promising antitumor activity and manageable safety of sintilimab-lenvatinib conversion therapy. The current study aimed to evaluate long-term survival outcomes in patients with unresectable hepatocellu...
Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming [0.03%]
低剂量放疗通过抗肿瘤中性粒细胞编程与PD-1阻断协同作用以达到晚期非小细胞肺癌的长期生存率
Laiyan Zhou,Yuanxin Liu,Zherui Xing et al.
Laiyan Zhou et al.
The optimal strategy for combining radiotherapy (RT) and immunotherapy remains under intensive investigation. Here we developed TRIDENT (Triple Radio-Immunotherapy-Driven ENhanced Therapy), a novel triple-modality regimen combining immunomo...
Ganji Purnachandra Nagaraju,Haasita Nellipudi,Chaithanya Ganji et al.
Ganji Purnachandra Nagaraju et al.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and aggressive tumor types, with a dismal 5-year survival rate of less than 15%. Despite major advances in understanding PDAC biology, therapeutic progress has been limited. ...
ENO2 drives tumor cell-induced M2 macrophage polarization to promote colorectal cancer liver metastasis [0.03%]
Junwei Tang,Zhihao Chen,Dongsheng Zhang et al.
Junwei Tang et al.
Liver metastasis is the primary cause of mortality in colorectal cancer (CRC) patients. To decipher the underlying mechanisms, we performed single-cell RNA sequencing (scRNA-seq) on paired primary colorectal tumors, adjacent tissues and liv...
Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study [0.03%]
Junwei Tang,Lu Wang,Sheng Yang et al.
Junwei Tang et al.
Neoadjuvant therapy has become a cornerstone in the management of locally advanced rectal cancer (LARC). In this single-arm, open-label phase II study, we evaluated the efficacy and safety of total neoadjuvant chemotherapy (TNT) using a Cap...
Harnessing pre-existing measles immunity: mRNA-Lipid nanoparticle-mediated measles hemagglutinin expression boosts antitumor CD8⁺ T cell responses [0.03%]
Javier Martínez-Latorre,Paula M Soriano-Teruel,Vicente Candela-Noguera et al.
Javier Martínez-Latorre et al.